A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia

Am J Hematol. 2021 Feb 1;96(2):E46-E50. doi: 10.1002/ajh.26043. Epub 2020 Nov 23.

Authors

Affiliations

¹ Penn State Cancer Institute, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
² Department of Public Health Sciences, Penn State University College of Medicine, Hershey, Pennsylvania, USA.

No abstract available

Keywords: AML; PD-1; T cell exhaustion; avelumab; decitabine.

Publication types

Clinical Trial, Phase I
Letter
Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Decitabine / administration & dosage
Decitabine / adverse effects
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*
Male
Middle Aged

Substances

Antibodies, Monoclonal, Humanized
Decitabine
avelumab